This suggests the importance of characterizing which BRD4 variants (both described here and beyond our study) become deregulated in a particular cancer type, as they can exert oncogenic or tumor suppressive roles (in an isoform-specific manner) and may inform the most appropriate strategies for targeted therapy. The gene discussed is BRD4; the disease is cancer.